PBI2 Real-World Evaluation of Biosimilar Bevacizumab-awwb versus Reference Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in a U.S. Integrated Healthcare Delivery System: 6-Month Interim Analysis

Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.073
https://www.valueinhealthjournal.com/article/S1098-3015(21)00290-4/fulltext
Title : PBI2 Real-World Evaluation of Biosimilar Bevacizumab-awwb versus Reference Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in a U.S. Integrated Healthcare Delivery System: 6-Month Interim Analysis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00290-4&doi=10.1016/j.jval.2021.04.073
First page :
Section Title :
Open access? : No
Section Order : 10201
Categories :
Tags :
Regions :
ViH Article Tags :